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SUMMARY
To assess factors that influence the choice of induction regimen in contem-
porary kidney transplantation, we examined center-identified, national
transplant registry data for 166 776 US recipients (2005–2014). Bilevel
hierarchical models were constructed, wherein use of each regimen was
compared pairwise with use of interleukin-2 receptor blocking antibodies
(IL2rAb). Overall, 82% of patients received induction, including thy-
moglobulin (TMG, 46%), IL2rAb (22%), alemtuzumab (ALEM, 13%), and
other agents (1%). However, proportions of patients receiving induction
varied widely across centers (0–100%). Recipients of living donor trans-
plants and self-pay patients were less likely to receive induction treatment.
Clinical factors associated with use of TMG or ALEM (vs. IL2rAb)
included age, black race, sensitization, retransplant status, nonstandard
deceased donor, and delayed graft function. However, these characteristics
explained only 10–33% of observed variation. Based on intraclass correla-
tion analysis, “center effect” explained most of the variation in TMG
(58%), ALEM (66%), other (51%), and no induction (58%) use. Median
odds ratios generated from case-factor adjusted models (7.66–11.19) also
supported large differences in the likelihood of induction choices between
centers. The wide variation in induction therapy choice across US trans-
plant centers is not dominantly explained by differences in patient or
donor characteristics; rather, it reflects center choice and practice.
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Introduction
Induction therapy in kidney transplantation is a strategy
to induce a rapid and profound reduction in immune
responses against an allograft to mitigate the higher risk
of acute rejection in the early post-transplant period.
This reduction in immune response is achieved by elim-
inating T and B lymphocytes that initiate and maintain
the immune response, by cell-depleting agents, or by
blocking interleukin-2 activity critical to activation and
sustenance of immunologic injury (interleukin-2 recep-
tor blocking antibodies, IL2rAb) [1]. While induction
therapy has been demonstrated to reduce the risk of
acute rejection and improve long-term allograft survival,
it can increase the risk of immunosuppression-related
complications such as infections or malignancies [2–6].
Commonly used agents have varying risk profiles, and
choosing among the available agents requires clinicians
to balance the patient’s risk of rejection with his or her
expected rate of complications given clinical and donor
organ characteristics (e.g., deceased vs. living donor).
In 2009, the Kidney Disease Improving Global Out-
comes guideline for “Care of Kidney Transplant Recipi-
ents” recommended induction therapy in all kidney
transplant recipients (1A) [7]. This guideline also rec-
ommended IL2rAb for first-line induction therapy (1B),
while offering a class 2B recommendation for use of
cell-depleting agents in patients considered “high risk”
for acute rejection. Increased immunological risk has
been associated with black race, allosensitization,
retransplantation, and younger age [7–10]. Recipients of
organs believed to be at greater risk of delayed graft
function or rejection, such as more donor–recipient
human leukocyte antigen (HLA) mismatches, longer
cold ischemic time, and higher kidney donor profile
index, may also warrant stronger induction therapy [8].
In addition to considering immunological risks, clini-
cians modify their choice of induction agent to facilitate
steroid-free or belatacept-based maintenance therapy, to
reduce the risk of steroid- or calcineurin-inhibitor-
related complications, or to mitigate concerns about
patient compliance.
Until recently, IL2rAb was the only induction agent
approved by the US Food and Drug Administration
(FDA) for induction immunosuppression in kidney
transplantation. Cell-depleting agents including thy-
moglobulin (TMG) and alemtuzumab (ALEM) have
been used off-label for this indication [11], although
TMG received an induction indication in April 2017
[12]. In 2014, 90% of kidney transplant recipients
received induction therapy. Despite the FDA approval
status, use of IL2rAb fell from 35% in 2004 to 20% in
2014, while use of T-cell-depleting agents (including
TMG, ALEM) continued to increase, from 39% in 2004
to 62% in 2015 [13].
Current national data suggest greater use of cell-
depleting agents than would be expected based on inter-
national guidelines. To better understand factors that
contribute to the choice of induction therapy, we exam-
ine center-level variation after adjusting for differences
in donor and recipient characteristics, using data from
the Scientific Registry of Transplant Recipients (SRTR).
This study extends work by our group quantifying vari-
ation in US maintenance immunosuppression practices
using a similar analytic framework [14].
Methods
Data source
The SRTR includes data on all transplant candidates,
recipients, and donors in the United States, submitted
by the members of the Organ Procurement and Trans-
plantation Network (OPTN). Additional data are drawn
from the Centers for Medicare & Medicaid Services and
the Social Security Death Master File. The Health
Resources and Services Administration, US Department
of Health and Human Services, provides oversight of
the activities of the OPTN and SRTR contractors. We
included patients who underwent kidney transplant in
the United States from 2005 to 2014.
Sample and induction regimens
Induction immunosuppression was defined by center
reporting to the registry, and categorized as IL2rAb,
TMG, ALEM, other induction (ATGAM, OKT3, ritux-
imab), or no induction. Induction use in the registry is
recorded as a binary indication (given or not), includ-
ing the indication (discriminating use for induction vs.
treatment of acute rejection), but information on dose
and days of treatment is not available. If use of two
induction agents was reported, precedence was given to
depleting agents per our prior methodology [15].
IL2rAb was chosen as the reference given its FDA
approval during the study period.
Case factors
Donor (age, type, cold ischemic time), recipient (age,
sex, race, body mass index, cause of end-stage renal dis-
ease, time on dialysis, panel-reactive antibody level
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[PRA] level), and transplant (HLA mismatch, previous
transplant, year, primary payer) characteristics were
extracted from the SRTR data for incorporation into
multivariate models. We categorized maintenance
immunosuppression based on data at discharge using the
following taxonomy: Triple therapy—tacrolimus (Tac),
mycophenolic acid (mycophenolate mofetil, mycopheno-
late sodium) or azathioprine (MPA/AZA), and pred-
nisone (Pred); steroid-sparing—Tac + MPA/AZA; MPA/
AZA-sparing—Tac alone, or Tac + Pred; mammalian
target of rapamycin inhibitor (mTORi)-based—sirolimus
(SRL) or everolimus (ERL), with or without Tac or
cyclosporine (CsA); CsA-based—CsA without SRL or
ERL; other maintenance regimens (Table 1).
Analyses
Observed variation in regimen use across centers
To visually assess unadjusted variation in induction use at
the center level across the United States, the observed pro-
portion of patients receiving each induction regimen was
determined and displayed as stacked bar plots. Plots were
also stratified by immunological risk, wherein high risk
was defined as black race, PRA >20, or retransplantation.
Combined center and case-level modeling
Bilevel hierarchical models were constructed to adjust
for clustering effects, similar to previous methods
[14,16–18]. Level 1 comprised patient/donor and trans-
plant (case) factors, and level 2 represented the center,
wherein use of each alternative regimen was compared
individually to the reference regimen (pairwise). Empiri-
cal Bayes estimates (EBEs) provided the adjusted pro-
portion (with 95% confidence intervals, CIs) of use of a
regimen of interest compared with the reference regi-
men, incorporating case-mix adjustment from the hier-
archical model. If the 95% CI for a center’s EBE of use
of a regimen of interest did not include the median
national rate of use, this indicated a prescribing pattern
statistically significantly different from the expected rate
of use for that regimen.
Heterogeneity in induction immunosuppression pre-
scribing across centers was quantified using intraclass
correlation (ICC) and median odds ratios (MOR). ICC
is defined as the ratio of cluster variance (center impact)
to the total observed variance in induction use, with
contributions in our study framework defined as center-
related, case-related, and other unmeasured effects. In
this context, the ICC quantifies the proportion of total
variance in induction use that is accounted for by center.
The MOR provides the median of the odds that patients
with identical characteristics will receive the induction
regimen of interest when two centers are drawn at ran-
dom (performed for all possible pairs of centers). For
example, a MOR of 2.0 means that if centers are selected
at random across all centers, a patient with a given set of
characteristics has, on an average, twice the odds of
receiving the induction regimen of interest at one of the
randomly selected centers than at the other [19]. The
adjusted odds ratios of receiving an induction regimen
other than the IL2rAb reference were determined for case
factors, after accounting for the center effect using the
hierarchical model. Data were analyzed using STATA 14,
College Station, TX, USA.
Contributions of case-level factors to variation in induction use
To quantify the degree to which variance in induction
regimen use was explained by recipient and donor char-
acteristics, we performed multivariate logistic regression
modeling with induction regimen as the dependent
variable and case factors as the predictors. Pairwise
models were constructed to assess the relative likelihood
of using each specific regimen (as outlined above) com-
pared with IL2rAb induction.
Results
Among 166 776 kidney transplants performed from 2005
through 2014 at 266 US centers, 81.8% of recipients were
treated with induction. TMG was the most commonly
used induction agent (46.0%), followed by IL2R-Ab
(21.9%), ALEM (12.5%), and other agents (1.3%)
(Table 1). Other induction comprised ATGAM (84.3%),
OKT3 (12.6%), and rituximab (4.6%). Nationally, ALEM
use increased in recent years, while use of IL2rAb, other,
and no induction decreased (Figure 1). More common
use of TMG was apparent when center-level use was
stratified by recipient immunologic risk (Appendix 1).
Patient and donor correlates with choice of regimen
Choice of induction therapy was associated with certain
patient and donor characteristics. Overall, TMG use was
more common in higher- than in lower-risk recipients
(52.0% vs. 40.5%), while IL2rAb use was less common
in higher- than in lower-risk recipients (15.9% vs.
27.7%) (Figure 2). In multilevel modeling considering
center and case factors, IL2rAb use was more common
in recipients who were children, white, and who
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Table 1. Recipient, donor, and transplant characteristics according to kidney transplant induction immunosuppression
regimen.
IL2rAb
(N = 36 600)
Thymoglobulin
(N = 76 726)
Alemtuzumab
(N = 20 874)
Other induction
(N = 2094)
No induction
(N = 30 422)
% % % % %
Maintenance immunosuppression ‡ ‡ ‡ ‡
Tac + MPA/AZA + Pred 68.8 59.0 24.3 59.8 45.5
Tac + MPA/AZA 11.8 27.9 62.3 30.0 14.1
Tac alone or Tac + Pred 1.5 1.4 7.4 1.9 2.8
mTORi-based 4.6 4.9 1.0 2.2 5.3
CsA-based 9.7 3.6 1.8 3.2 3.0
Other or unknown 3.6 3.3 3.3 2.9 29.4
Recipient factors
Female 35.3 41.1‡ 40.1‡ 42.6‡ 38.0‡
Age, years ‡ ‡ * ‡
<18 8.3 4.3 3.2 4.3 6.9
18–30 8.4 8.3 8.6 9.5 9.0
31–45 17.9 21.3 21.9 22.7 20.8
46–60 33.7 37.9 38.9 38.1 35.7
>60 31.7 28.2 27.4 25.3 27.6
Race ‡ ‡ ‡ ‡
White 56.2 51.0 54.3 52.0 52.5
Black 18.0 27.4 26.1 18.5 26.3
Hispanic 17.1 14.5 14.7 14.9 14.7
Other 8.7 7.0 4.8 14.6 6.5
Body mass index, kg/m2 ‡ ‡ ‡
<18.5 5.8 3.8 3.3 4.4 4.5
18.5 to <25 31.4 29.8 28.0 33.6 26.4
25 to <30 31.7 31.2 31.3 30.4 26.0
≥30 28.2 31.1 35.2 28.4 24.6
Unknown 2.8 4.0 2.3 3.3 18.6
Cause of ESRD ‡ ‡ ‡ ‡
Diabetes 23.5 22.7 23.8 23.8 20.9
Glomerulonephritis 23.7 23.9 23.6 27.3 21.9
Hypertension 21.4 26.2 25.0 17.1 27.5
Polycystic kidney disease 9.9 9.6 10.6 8.8 9.8
Other 21.5 17.7 17.1 23.1 19.9
Hypertension 76.9 81.6‡ 80.6‡ 83.0‡ 78.1‡
Dialysis duration, months ‡ ‡ ‡ ‡
None 19.8 15.6 19.3 16.3 18.0
0–24 34.5 29.1 31.5 29.2 30.7
25–60 28.3 32.0 29.1 31.4 27.3
>60 16.4 22.3 19.4 22.0 19.0
Unknown 1.1 0.9 0.8 1.1 5.1
Most recent PRA ‡ † ‡
0–9 71.8 56.8 60.8 52.9 61.7
10–79 19.3 25.9 25.6 29.3 23.3
≥80 4.2 13.5 11.1 15.1 9.5
Unknown 4.7 3.8 2.5 2.7 5.5
Previous transplant 8.9 16.2‡ 12.5‡ 16.3‡ 13.1‡
Primary payer ‡ ‡ ‡
Private 40.6 36.1 40.6 36.3 36.9
Public 59.1 63.5 59.1 63.4 53.7
Self/Other 0.4 0.4 0.4 0.3 9.3
Donor and transplant factors
HLA mismatches ‡ ‡ ‡ ‡
Zero 10.2 8.0 7.7 10.3 11.0
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underwent preemptive transplant (Table 2). Conversely,
recipients who were black or highly sensitized, or who
experienced delayed graft function or had longer pre-
transplant dialysis duration, were more likely to be trea-
ted with cell-depleting agents (ALEM, TMG). Choice of
induction regimen was also strongly correlated with
post-transplant maintenance regimen. Patients dis-
charged on triple therapy (Tac + MPA/AZA + Pred)
were more likely to receive IL2rAb, compared with all
other induction agents. ALEM (62.3%) administration
was more common in steroid-free maintenance regi-
mens (Tac + MPA/AZA).
Center-level variation in induction regimen use
The proportion of patients treated with each induction
agent varied widely across centers: IL2rAb (0–99%),
TMG (0–100%), ALEM (0–84%), none (0–97%), and
also varied within each of the 11 regions across the
country (Figure 3).
After adjustment for differences in donor and recipi-
ent characteristics using hierarchical logistic regression
models, the observed between-center variation in use of
specific induction regimens was significantly greater than
what would be expected (Table 3, Figure 4). Based on
EBEs and pairwise comparison of relative use of TMG
versus IL2rAb, use rates at 44.7% of centers were lower
than expected. While only 46.0% of centers used any
ALEM, 38.7% of those used it significantly more than
the estimated national average ratio of ALEM to IL2rAb.
Nearly, 36% of centers used induction-free immunosup-
pression more commonly than expected. After adjust-
ment for donor and recipient characteristics, the ICCs
suggested that most variation in TMG (58%), ALEM
Table 1. Continued.
IL2rAb
(N = 36 600)
Thymoglobulin
(N = 76 726)
Alemtuzumab
(N = 20 874)
Other induction
(N = 2094)
No induction
(N = 30 422)
1–3 31.4 27.0 31.5 25.3 29.9
4–5 45.1 50.9 47.5 49.8 44.9
6 12.9 13.8 13.0 13.6 12.8
Unknown 0.5 0.3 0.3 1.1 1.3
Donor type ‡ ‡ ‡ ‡
SCD 40.8 47.6 39.6 51.4 40.0
ECD 8.5 10.1 9.7 6.8 9.9
DCD 6.1 10.0 9.2 10.8 7.7
Living related 26.9 16.5 21.9 17.4 24.9
Living unrelated 17.6 15.8 19.6 13.6 17.5
Donor age, years ‡ † ‡ †
<18 7.9 9.1 6.9 10.5 7.8
18–30 21.8 21.8 21.5 24.3 21.3
31–45 29.5 28.2 29.7 28.4 29.1
46–60 33.1 33.4 34.0 31.1 33.2
>60 7.7 7.5 7.9 5.7 8.7
Cold ischemia time, hrs ‡ ‡ ‡ ‡
Living donor (N/A) 9.2 6.2 9.6 4.6 9.7
0–12 52.4 44.6 45.6 48.1 46.3
13–24 28.0 33.2 30.6 35.6 22.9
≥24 9.0 13.6 12.7 10.4 12.6
Unknown 1.3 2.5 1.5 1.3 8.4
Delayed graft function 13.1 18.9‡ 15.5‡ 21.0‡ 15.4‡
Transplant year ‡ ‡ ‡
2005–2008 43.3 35.7 30.5 37.5 47.3
2009–2011 29.4 30.7 31.7 36.1 21.7
2012–2014 27.3 33.6 37.8 26.5 31.0
AZA, azathioprine; CsA, cyclosporine; DCD, donation after circulatory death; ECD, expanded criteria donor; ESRD, end-stage
renal disease; HLA, human leukocyte antigen; IL2rAb, interleukin-2 receptor blocking antibodies; MPA, mycophenolate acid;
mTORi, mammalian target of rapamycin inhibitor; N/A, not applicable; PRA, panel-reactive antibody; Pred, prednisone; SCD,
standard criteria donor; Tac, tacrolimus.
P-values: *P < 0.05–0.002; †0.001–0.0001; ‡P < 0.0001.
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(66%), other induction (61%), and no induction (58%)
use reflected center practice, which is not explained by
differences in the treated populations or the organs that
were transplanted (Table 4).
Discussion
We examined the impact of center and case factors on
induction regimen choice in contemporary US kidney
transplant practice, and found that regimens varied
widely across centers and also varied widely within each
of the UNOS regions across the country. We confirmed
that choice of induction regimen was associated with
some donor and recipient factors; however, these factors
explained only a minority of the variation observed
nationally. After adjustment for clinical characteristics,
most of observed variation in choice of a non-IL2rAb
regimen reflected center practice patterns rather than
recipient or donor factors.
Two landmark trials established the efficacy of induc-
tion agents in reducing the risk of rejection in patients
at high immunological risk of rejection. In 2006, Bren-
nan et al. [8] compared the efficacy and safety of TMG
versus basiliximab (IL2rAb). Among patients catego-
rized as at high risk of rejection and delayed graft func-
tion, incidence of acute rejection was lower in the TMG
arm, and patient and graft survival were similar at
1 year. The overall risk of infections was significantly
higher in the TMG arm, although the rate of cytomega-
lovirus infection was lower. A 10-year follow-up based
on linkage of US study participants to the national
transplant registry revealed similar patient and allograft
survival in TMG- and basiliximab-treated patients over
long-term follow-up, while the cumulative incidence of
acute rejection remained lower in the TMG group [20].
No difference was found in risk of other infections or
post-transplant cancers. Notably, registry data may not
identify serial changes in maintenance immunosuppres-
sion and patient compliance, and registry-based rejec-
tion and complications data may lack granularity.
In 2011, Hanaway et al. [21] reported a randomized
comparison of TMG versus ALEM among recipients at
higher immunological risk, and ALEM versus IL2rAb
(specifically basiliximab) among recipients at lower risk
(“INTAC” Study). All patients received Tac, MMF, and
a rapid steroid withdrawal protocol. The study demon-
strated that ALEM was superior to basiliximab even
among recipients at lower immunological risk in pre-
venting acute rejection; however, there was no differ-
ence in acute rejection with TMG versus ALEM in
Figure 1 National trends in kidney transplant induction over time. IL2rAb, interleukin-2 receptor blocking antibodies.
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Figure 2 National trends in kidney transplant induction by recipient
immunologic risk profile. High risk was defined as black race, PRA
>20, or retransplantation. ALEM, alemtuzumab; IL2rAb, interleukin-2
receptor blocking antibodies; PRA, panel-reactive antibody; TMG,
thymoglobulin.
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Table 2. Associations of recipient, donor, and transplant case characteristics with induction regimen use compared to
IL2rAb (reference regimen).
Thymoglobulin Alemtuzumab Other induction No induction
Adjusted odds ratio (95% CI)
Maintenance immunosuppression
Tac + MPA/AZA + Pred Reference Reference Reference Reference
Tac + MPA/AZA 2.03 (1.90, 2.18)‡ 14.08 (12.83, 15.44)‡ 2.98 (2.46, 3.61)‡ 1.60 (1.47, 1.74)‡
Tac alone or Tac + Pred 0.80 (0.67, 0.95)* 14.82 (12.11, 18.15)‡ 0.94 (0.59, 1.49) 2.06 (1.77, 2.40)‡
mTORi-based 1.05 (0.92, 1.20) 2.04 (1.62, 2.56)‡ 0.69 (0.43, 1.11) 1.12 (0.99, 1.27)
CsA-based 0.54 (0.49, 0.60)‡ 1.01 (0.83, 1.22) 0.82 (0.58, 1.15) 0.83 (0.75, 0.92)‡
Other or unknown 0.78 (0.70, 0.87)‡ 3.48 (2.97, 4.09)‡ 0.94 (0.65, 1.35) 5.05 (4.61, 5.54)‡
Recipient factors
Female 1.27 (1.21, 1.32)‡ 1.22 (1.14, 1.31)‡ 1.26 (1.09, 1.45)† 1.08 (1.03, 1.13)†
Age, years
<18 0.62 (0.55, 0.71)‡ 0.31 (0.25, 0.39)‡ 0.67 (0.43, 1.04) 0.68 (0.59, 0.77)‡
18–30 1.02 (0.93, 1.11) 0.91 (0.79, 1.04) 1.12 (0.85, 1.47) 1.00 (0.92, 1.10)
31–45 Reference Reference Reference Reference
46–60 0.92 (0.87, 0.98)* 0.79 (0.72, 0.87)‡ 0.90 (0.74, 1.08) 0.90 (0.85, 0.97)*
>60 0.63 (0.59, 0.67)‡ 0.44 (0.40, 0.49)‡ 0.44 (0.36, 0.55)‡ 0.76 (0.71, 0.82)‡
Race
White Reference Reference Reference Reference
Black 1.51 (1.42, 1.61)‡ 1.25 (1.14, 1.38)‡ 1.63 (1.33, 2.00)‡ 1.07 (1.00, 1.14)*
Hispanic 1.06 (0.99, 1.13) 1.11 (0.99, 1.24) 1.24 (1.00, 1.54) 1.01 (0.94, 1.09)
Other 1.07 (0.98, 1.16) 1.15 (0.99, 1.33) 1.10 (0.87, 1.40) 1.04 (0.94, 1.14)
Body mass index, kg/m2
<18.5 0.83 (0.74, 0.93)† 0.78 (0.65, 0.94)* 1.01 (0.73, 1.41) 0.96 (0.86, 1.09)
18.5 to <25 Reference Reference Reference Reference
25 to <30 1.04 (0.99, 1.09) 1.08 (0.99, 1.17) 0.95 (0.80, 1.13) 0.99 (0.94, 1.05)
≥30 1.14 (1.08, 1.21)‡ 1.24 (1.13, 1.35)‡ 1.06 (0.88, 1.27) 1.02 (0.96, 1.08)
Unknown 0.77 (0.67, 0.89)‡ 0.74 (0.59, 0.94)* 2.01 (1.38, 2.93)‡ 2.56 (2.28, 2.87)‡
Cause of ESRD
Diabetes Reference Reference Reference Reference
Glomerulonephritis 1.07 (1.00, 1.14)* 1.03 (0.93, 1.14) 0.98 (0.80, 1.21) 0.95 (0.89, 1.02)
Hypertension 1.06 (0.99, 1.12) 1.03 (0.92, 1.14) 1.03 (0.83, 1.28) 1.04 (0.97, 1.11)
Polycystic kidney disease 1.05 (0.97, 1.14) 1.17 (1.03, 1.33)* 0.80 (0.61, 1.05) 0.98 (0.89, 1.07)
Other 0.92 (0.86, 0.98)* 0.93 (0.83, 1.04) 0.86 (0.69, 1.07) 0.93 (0.86, 1.01)
Hypertension 0.97 (0.92, 1.03) 1.23 (1.12, 1.34)‡ 0.88 (0.73, 1.07) 0.80 (0.76, 0.86)‡
Previous transplant 1.92 (1.79, 2.06)‡ 1.10 (0.99, 1.23) 1.22 (0.99, 1.51) 1.09 (1.00, 1.18)*
Dialysis duration, months
Preemptive 0.94 (0.89, 1.00) 1.03 (0.94, 1.13) 1.05 (0.86, 1.29) 1.03 (0.96, 1.10)
0–24 Reference Reference Reference Reference
25–60 1.10 (1.03, 1.16)† 1.08 (0.98, 1.18) 0.79 (0.66, 0.95)* 1.07 (1.00, 1.14)*
>60 1.25 (1.16, 1.34)‡ 1.19 (1.05, 1.33)* 0.92 (0.73, 1.15) 1.07 (0.99, 1.16)
Unknown 0.80 (0.65, 0.99)* 1.08 (0.78, 1.50) 0.88 (0.45, 1.75) 2.14 (1.80, 2.55)‡
Peak PRA level
0–9 Reference Reference Reference Reference
10–79 1.90 (1.81, 2.01)‡ 1.56 (1.43, 1.70)‡ 1.93 (1.63, 2.28)‡ 1.27 (1.20, 1.35)‡
≥80 4.82 (4.40, 5.28)‡ 4.30 (3.74, 4.96)‡ 6.83 (5.21, 8.93)‡ 1.94 (1.75, 2.16)‡
Unknown 0.95 (0.86, 1.05) 0.71 (0.58, 0.87)† 1.58 (1.07, 2.35)* 1.30 (1.15, 1.47)‡
Primary payer
Private 1.09 (1.04, 1.15)‡ 1.16 (1.07, 1.26)‡ 1.14 (0.97, 1.34) 1.01 (0.96, 1.07)
Public Reference Reference Reference Reference
Self/Other 1.00 (0.70, 1.42) 2.05 (1.23, 3.42)* 0.99 (0.34, 2.89) 6.64 (5.18, 8.51)‡
Donor and transplant factors
HLA mismatches
Zero 0.56 (0.52, 0.61)‡ 0.38 (0.33, 0.43)‡ 0.60 (0.46, 0.77)‡ 1.10 (1.01, 1.19)*
204 Transplant International 2018; 31: 198–211
ª 2017 Steunstichting ESOT
Dharnidharka et al.
higher-risk recipients. The overall risk of adverse events
at 3 years was similar in all groups, although the ALEM
group experienced more serious infections (vs. basilix-
imab), and more cancers (vs. basiliximab and TMG
combined). We found increased use of cell-depleting
agents in recipients at higher immunological risk (e.g.,
black race, allosensitized, previous transplant) in our
study, perhaps driven by such trial results.
In contrast to the benefits among high immunologic
risk patients, the benefits of TMG in lower immunologic
risk patients are less clear. A 2009 Cochrane meta-
analysis examined 71 randomized clinical trials comparing
different induction therapy [22]. The reviewed trials
dominantly enrolled low immunological risk recipients,
with 72% being first-time transplant recipients. Eighteen
of the 71 included studies compared TMG to IL2rAb,
and found no differences in graft loss at any point or
in the rate of clinically diagnosed acute rejection.
However, TMG decreased the rate of biopsy-proven
acute rejection.
Randomized clinical trials offer an unparalleled level
of evidence, but inclusion criteria can be selective, fol-
low-up is short, and the care provided within the
framework of a trial may not represent real-world prac-
tice. While limited in granularity and lack of random-
ization, large database studies can provide increased
power, better generalizability, and longer follow-up.
One study of national registry data for US transplant
recipients in 2001 to 2005, using exposure likelihood
and outcome risk matching techniques to minimize the
risk of confounding, found lower risk of a 6-month
composite of acute rejection, death, or graft failure
among patients who received TMG compared to basilix-
imab, across statistical approaches [23]. More recently,
Table 2. Continued.
Thymoglobulin Alemtuzumab Other induction No induction
Adjusted odds ratio (95% CI)
1–3 Reference Reference Reference Reference
4–5 0.99 (0.93, 1.04) 0.94 (0.86, 1.02) 0.99 (0.82, 1.19) 1.00 (0.94, 1.06)
6 1.00 (0.93, 1.07) 0.94 (0.83, 1.06) 1.06 (0.83, 1.35) 0.95 (0.88, 1.04)
Unknown 1.05 (0.71, 1.55) 0.95 (0.56, 1.61) 0.80 (0.34, 1.87) 0.97 (0.72, 1.32)
Donor type
SCD Reference Reference Reference Reference
ECD 1.27 (1.16, 1.39)‡ 1.20 (1.03, 1.39)* 0.95 (0.69, 1.31) 1.05 (0.95, 1.17)
DCD 1.49 (1.37, 1.62)‡ 1.38 (1.21, 1.57)‡ 1.34 (1.03, 1.74)* 1.21 (1.10, 1.34)
Living related 0.62 (0.57, 0.68)‡ 0.75 (0.66, 0.86)‡ 0.54 (0.42, 0.71)‡ 0.96 (0.88, 1.05)
Living unrelated 0.80 (0.73, 0.86)‡ 0.94 (0.83, 1.08) 0.64 (0.49, 0.83)† 0.86 (0.79, 0.94)†
Donor age, years
<18 1.01 (0.92, 1.10) 0.99 (0.86, 1.15) 1.12 (0.86, 1.46) 1.09 (0.99, 1.20)
18–30 0.91 (0.86, 0.97)* 1.01 (0.91, 1.11) 0.96 (0.79, 1.16) 0.98 (0.92, 1.04)
31–45 Reference Reference Reference Reference
46–60 0.93 (0.88, 0.98)* 0.97 (0.89, 1.06) 0.95 (0.80, 1.14) 0.97 (0.91, 1.03)*
>60 0.88 (0.80, 0.98)* 0.89 (0.76, 1.04) 0.74 (0.52, 1.04) 1.04 (0.93, 1.16)
Cold ischemia time, hrs
Living donor (N/A) 1.06 (0.97, 1.16) 1.17 (1.02, 1.34)* 1.48 (1.07, 2.04)* 1.40 (1.27, 1.54)‡
0–12 Reference Reference Reference Reference
13–24 1.24 (1.16, 1.32)‡ 1.16 (1.04, 1.29)* 1.16 (0.96, 1.40) 0.94 (0.87, 1.01)
≥24 1.38 (1.27, 1.50)‡ 1.20 (1.05, 1.38)* 1.13 (0.87, 1.47) 0.93 (0.85, 1.02)
Unknown 1.59 (1.32, 1.90)‡ 1.07 (0.80, 1.44) 1.23 (0.61, 2.49) 2.76 (2.36, 3.23)‡
Delayed graft function 1.79 (1.68, 1.90)‡ 1.13 (1.02, 1.25)* 1.48 (1.22, 1.80)‡ 1.07 (1.00, 1.15)
Transplant year
2005–2008 Reference Reference Reference Reference
2009–2011 1.05 (0.99, 1.10) 1.56 (1.43, 1.71)‡ 0.98 (0.82, 1.16) 0.74 (0.70, 0.79)‡
2012–2014 1.09 (1.03, 1.15)† 3.63 (3.31, 3.98)‡ 1.02 (0.84, 1.23) 0.76 (0.71, 0.81)‡
AZA, azathioprine; CsA, cyclosporine; DCD, donation after circulatory death; ECD, expanded criteria donor; ESRD, end-stage
renal disease; HLA, human leukocyte antigen; IL2rAb, interleukin-2 receptor blocking antibodies; MPA, mycophenolate acid;
mTORi, mammalian target of rapamycin inhibitor; N/A, not applicable; PRA, panel-reactive antibody; Pred, prednisone; SCD,
standard criteria donor; Tac, tacrolimus.
P-values: *P < 0.05–0.002; †0.001–0.0001; ‡P < 0.0001.
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a study by Koyawala et al. based on linking US registry
data to Medicare claims (2003–2008) and matching
patients based on many demographic and clinical fac-
tors, found that ALEM was associated with 14% higher
adjusted mortality, 18% higher all-cause graft failure
and 31% higher acute rejection compared to TMG.
IL2rAb (basiliximab) was associated with 8% increased
mortality and 16% higher acute rejection but no
increase in the risk of all-cause graft failure compared
to TMG [24]. Results for the ALEM versus TMG com-
parisons were generally consistent across subgroups
including elderly patients and those receiving pred-
nisone. In contrast, higher mortality for IL2rAb versus
TMG was not confirmed in subgroup analyses. With
regard to outcomes in specific subgroups, a recent ret-
rospective analysis of African American kidney trans-
plant recipients identified in US registry data found
that, compared to IL2rAb induction, depleting induc-
tion (including TMG, ALEM, or OKT3) was associated
with 32% reduction in acute rejection, 9% lower graft
loss, and 12% lower mortality over up to 14 years of
follow-up [9]. Another registry-based study focused on
retransplant recipients, and found that compared to
patients induced with TMG, no induction was associ-
ated with 82% greater adjusted likelihood of early acute
rejection, while IL2rAb induction was associated with
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Figure 3 Proportion of patients receiving each induction immunosuppression regimen (including no induction) across US transplant centers
(2005–2014). Each horizontal bar represents an individual center within US OPNT Regions, ordered by the proportion of patients receiving each
regimen. Overall percentages of regimen use at patient level across centers: TMG, 46.0%; IL2rAb, 21.9%; ALEM, 12.5%; other induction,
1.3%; no induction, 18.2%. ALEM, alemtuzumab; IL2rAb, interleukin-2 receptor blocking antibodies; TMG, thymoglobulin.
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more than twice the likelihood of early acute rejection
[10]. There were no differences in patient or graft sur-
vival with TMG versus IL2rAb treatment in the retrans-
plant population.
Previous studies have suggested benefit of specific
induction agents when combined with steroid avoidance
or MPA-sparing maintenance regimens. We found that
ALEM use was almost 14-fold higher than IL2rAb use
Table 3. Center-level empirical Bayes estimates adjusted for case-level characteristics*.
Immunosuppression
regimen
(Reference: IL2rAb)
No. of centers
in pairwise
comparison
No. of centers
significantly
above reference
probability (%)
No. of centers
significantly below
reference probability (%)
Thymoglobulin 253 105 (43.2) 116 (44.7)
Alemtuzumab 123 51 (38.7) 52 (10.5)
Other 132 40 (32.0) 38 (19.5)
No induction 256 89 (35.7) 115 (43.2)
IL2rAb, interleukin-2 receptor blocking antibodies.
*Constructed from pairwise comparisons of regimen of interest versus reference regimen (IL2rAb).
Figure 4 Empirical Bayes estimates for likelihood of induction regimen use compared with IL2rAb. Reference regimen based on current US
Food and Drug Administration approval during the study period. Red bar demonstrates national average rate of use of each regimen (within
pairwise regimen comparisons). Each red dot represents adjusted use at one center, and the blue bars reflect 95% confidence intervals for use
at the center determined by empirical Bayes estimates, adjusting for case factors of transplants at the center. Exclusion of the national average
by a 95% confidence interval reflects adjusted center use significantly above or below the national average. ICC, intraclass correlation coeffi-
cient; IL2rAb, interleukin-2 receptor blocking antibodies; MOR, median odds ratio; TMG, thymoglobulin.
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among patients receiving steroid-free regimens. Further-
more, ALEM use appeared to be higher among obese
patients, possibly due to the desire to withdraw steroids
once these patients were stable. The major differences
between TMG and ALEM use appear to be the prefer-
ence for using ALEM in steroid protocols and greater
use in recent years.
We demonstrated that center choice, rather than
patient or donor characteristics, was the primary driver
of induction immunosuppression regimen. The widest
variation in induction use was observed for ALEM.
ALEM was used at only 45.6% of centers analyzed.
Among centers that used ALEM, there was wide varia-
tion in the proportions of patients who received this
agent. The MOR data demonstrate that if two centers
were selected at random, the odds of a patient receiving
ALEM versus IL2rAb at one center were up to 11-fold
higher than at the other, even after accounting for
observed recipient, donor, and transplant characteristics.
The MORs for other induction regimens demonstrated
similarly high degrees of intercenter variation in use
compared with IL2rAb: TMG (7.64), other induction
(8.60), no Induction (7.66).
In concordance with prior national reports [13,25],
our data show an overall increase in use of induction
agents over time. While use of IL2rAb has decreased,
use of lymphocyte-depleting agents (both TMG and
ALEM) has increased. Economic factors may con-
tribute to the decision to use ALEM. Notably, in the
United States, ALEM was distributed for free for kid-
ney transplant induction under the Campath Distri-
bution Program, and upfront cost savings may have
been attractive given recognition that reimbursement
for kidney transplant has not kept pace with the rising
costs of the procedure [26], especially for underinsured
patients. In fact, our analyses showed two-fold higher
adjusted use of ALEM in self/other-pay patients, com-
pared with IL2rAb use. Based on the absolute whole-
sale price, the cost of basiliximab is $6490 per patient,
compared with the approximate cost of $10 000–
14 000 per patient (4.5–6.0 mg/kg dose for a 70 kg
patient) for TMG [27]. The Campath Distribution
Program is now restricted, which may limit further
expansion of ALEM use.
Importantly, consideration of cost of an agent alone
does not account for cost savings from reducing risks of
rejection, graft loss, or other complications. The clinical
benefit of appropriate induction therapy has been con-
firmed in recent analyses. In recipients of deceased
donor kidney transplants, TMG and ALEM reduced
acute rejection risks compared with IL2rAb, but only
TMG has been correlated with better graft survival [28].
In recipients of living donor transplants who were not
treated with steroids, both ALEM and TMG reduced
acute rejection risk compared with IL2rAb; however,
ALEM has been associated with higher composite risk
of graft failure or patient death, while TMG was not
[29]. Results with ALEM may improve over time as a
center becomes more experienced with the drug [30].
The retrospective study by Koyawala et al. [24] found
that 1-year resource utilization was slightly lower among
recipients treated with ALEM compared to TMG, but
did not differ between those treated with basiliximab
compared to TMG. When assessing cost-effectiveness of
induction agents in deceased donor kidney recipients,
Gharibi et al. [31] found that cell-depleting regimens
such as TMG and ALEM were more cost effective in
both high and low immunologic risk groups. Only
TMG was associated with graft survival benefit over no
induction.
Table 4. Heterogeneity across unadjusted and both adjusted models*.
Immunosuppression
Regimen
(Reference: IL2rAb)
Proportion of
variance in
hierarchical model
explained by center
characteristics (Unadjusted)
MOR
(Unadjusted)
Proportion of
variance in hierarchical
model explained
by center, adjusted
for donor/recipient
factors
MOR
(Adjusted)
Proportion
of variance in
model explained
by donor/recipient
characteristics
Thymoglobulin 0.55 6.76 0.58 7.64 0.11
Alemtuzumab 0.69 13.06 0.66 11.19 0.33
Other 0.58 7.69 0.61 8.60 0.10
No induction 0.56 7.00 0.58 7.66 0.12
ICC, intraclass correlation coefficient; IL2rAb, interleukin-2 receptor blocking antibodies; MOR, median odds ratio.
*Proportion of variance in hierarchical model is equal to the ICC.
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Limitations of our study include the binary definition
of induction use in the registry data. In addition, no
information was available on induction regimen sched-
ule or dosing, presence of donor-specific antibody, prior
malignancy or infections, or other clinical factors that
may have modified induction choice.
In conclusion, based on analyses of center-identified
national transplant registry data, we found that kidney
transplant induction therapy varies widely across US
transplant centers, and that choice of regimen largely
reflects center preference rather than patient or donor
characteristics. The variation in use of induction agents
presents several unique opportunities. First, the
observed variation can be used to help design transplant
outcomes studies to better target induction to patients
who are expected to derive the best outcomes. Second,
tools are needed to better guide clinicians to evidence-
based selection of regimens. Centers with the best
intermediate and long-term allograft and patient out-
comes should be examined to understand how much
of the improved performance is attributable to induc-
tion immunosuppression. Third, closer analyses of
cumulative infection and post-transplant malignancy
risk, and an economic analysis of overall costs attribu-
ted to induction immunosuppression, are needed. Fur-
ther research, including collaborative clinical trials and
secondary data analyses of contemporary practice, is
needed to determine the relationship between center
practice, post-transplant outcomes, and patient selec-
tion to advance from a “one size fits all” to a person-
alized medicine approach to immunosuppression.
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Appendix 1
Proportion of patients receiving each induction immunosuppression option (including no induction)
across US transplant centers (2005–2014), by clinical risk profile.
Center practice drives induction choice
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